Zafgen's Obesity Drug Continues to Cut the Fat in Phase 2 Trial

Published: Jun 24, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Zafgen raised eyebrows two years ago when it showed that its injectable drug, which changes the way the body metabolizes fat, helped severely obese people in a small clinical trial lose a lot of weight in the span of a month. Today, the Cambridge, MA-based company is giving a sneak peek into its next study—and, while it’s a tiny sample size, the numbers appear to be holding up. Cambridge, MA-based Zafgen today is releasing interim results at the 73rd American Diabetes Association Scientific Sessions from a 12-week mid-stage clinical trial testing the drug, named beloranib, in 160 severely obese patients—those with an average body mass index, or BMI, of 38. The results provide just a glimpse of the data. They account for just the first 19 patients out of the study, all female, of which only 14 were dosed with the drug rather than a placebo, according to Zafgen president and CEO Tom Hughes. But even so, they continued to show beloranib’s potential fat-zapping ability.

Help employers find you! Check out all the jobs and post your resume.

Back to news